Business Wire

New Clinical Data Support Nexodyn® AcidOxidizing Solution (AOS) To Reactivate the Physiological Healing Process of Chronic Wounds

Del

APR Applied Pharma Research sa (APR), the Swiss independent developer of science driven and patent protected healthcare products, today announces the publication in “Advances in skin & wound care” (April 2018) of the results of a clinical pilot study on the efficacy and tolerability of Nexodyn® AcidOxidizing Solution (AOS), a sprayable Active Cleanser with ancillary antimicrobial activity developed for acute and chronic wound management.

Results suggest how Nexodyn® AcidOxidizing Solution (AOS), thanks to its synergic and distinctive physico-chemical properties, could play a key role in the management of chronic wounds as it promotes effectively wound rebooting by creating the ideal microenvironment to sustain the physiological healing process and favoring an optimized lesion closure.

The pilot study was conducted with a prospective, single-arm design by Prof. Robert Strohal in Austria and engaged 30 patients with critically colonized or locally infected chronic leg ulcers of any origin. Along the study, Nexodyn® AcidOxidizing Solution (AOS) was applied on each leg ulcer at every dress change for 35 days together with a nonadherent gauze and a multi-purpose absorbent dressing.

By the end of the study period, treatment with Nexodyn® AcidOxidizing Solution (AOS) led to the full healing of 37% of the chronic wounds as well as to a significant decrease in wound size (P<.001). Moreover, thanks to Nexodyn® AcidOxidizing Solution (AOS) active cleansing properties, wound-associated infections were eliminated, together with a reduction in pH values and local bioburden covering the wound, whilst no reinfection of any examined wounds was observed during the study.

Based on the pilot study, it can be postulated that the application of Nexodyn® AcidOxidizing Solution (AOS) contributes to normalize the pH value of chronic wounds and influence positively biochemical reactions pivotal for rebooting physiological healing process.

Data also confirm Nexodyn® AcidOxidizing Solution (AOS) favorable safety and tolerability profile, especially relevant in chronic wounds, with no adverse events reported over the study duration, high levels of pain relief and comfort at application as well as wound-associated pain reduction.

Due to demographic changes in developed countries, chronic wound healing represents an emerging healthcare issue both from a clinical and social perspective: health care professionals agree that traditional therapeutic alternatives do not satisfactorily address the complex clinical picture.

According to a new market research, the Global Wound Cleanser Product market is anticipated to grow, from $1504.7 million in 2016 to $2171.4 million by 2023, growing at a CAGR of 5.4% (1)

“Nexodyn could fill the gap with the current demand from health care professionals and patients for a treatment option able to address the wound healing complexity” says Giorgio Reiner, Corporate R&D Director at APR – “as it offers the possibility to actively cleanse the wound, thus creating the ideal conditions for wound rebooting”.

As a science driven developer, APR is committed to provide a growing body of clinical evidence to further delineate Nexodyn® AcidOxidizing Solution (AOS) safety and efficacy profile as a wound rebooter.

Full publication “The Management of Critically Colonized and Locally Infected Leg Ulcers with an Acid-Oxidizing Solution: A Pilot Study” available at: https://journals.lww.com/aswcjournal/fulltext/2018/04000/The_Management_of_Critically_Colonized_and_Locally.5.aspx.

(1) Global Wound Cleanser Product Market – Analysis and Forecast (2016-2023) by BSI Research.

About Nexodyn® AcidOxidizing Solution (AOS)

Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.

A wide array of non-clinical experiments and clinical experiences and studies suggest Nexodyn® AcidOxidizing Solution (AOS) to perform as a Wound Rebooter by creating the ideal microenvironment to sustain the physiological healing process. Rebooting a wound, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.

Developed based on APR’s proprietary and patented technology TEHCLO®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).

Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, vascular ulcers), post-surgical wounds, burns and other lesions.

As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining wound rebooting to the benefit of patients and HCPs who can rely on the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable tolerability, with no pain exacerbation, for prolonged periods of use and across the wound healing continuum.

For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/#nexodyn-formula

About APR Applied Pharma Research sa

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti (CEO)
T: +41 91 6957020 or email to paolo.galfetti@apr.ch

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Nearly 1 Billion People Worldwide Have Sleep Apnea, International Sleep Experts Estimate21.5.2018 18:15Pressemelding

A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005096/en/ Woman wearing CPAP, the gold standard treatment for sleep apnea (Photo: Business Wire) The study “Global Prevalence of Obstructive Sleep Apnea (OSA)” was conducted by an international panel of leading researchers seeking to provide a clear scope of the impact of the chronic sleep-disordered breathing condition. The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. By analyzing technology improvements in detecting OSA and underreported statistics from other areas of the world, this latest study depicts an impacte

Pietro Rosa TBM Signs Long-Term Agreement with Pratt & Whitney21.5.2018 15:13Pressemelding

Pietro Rosa TBM (Turbine Blade Manufacturing) today announced that it has signed a 10-year, long-term agreement (LTA) with Pratt & Whitney, a division of United Technologies Corp., to supply airfoil products for both commercial and military engines. The LTA, which may extend to the entire Pietro Rosa TBM Group in Europe and the United States, will support Pratt & Whitney’s F135, PW2000 and the Geared Turbofan™ (GTF) family of engines. This agreement represents a significant step in the collaboration between the two companies, enabling the Pietro Rosa TBM Group to utilize its advanced engineering capabilities and the vertical integration of hot forming, machining and surface finishing technologies. “We’re pleased to sign this agreement with Pietro Rosa,” said Art Erikson, executive director of Strategic Sourcing, Pratt & Whitney. “We have tremendous growth ahead, and suppliers like Pietro Rosa that sign up to our contractual governance, commitment to cost competitiveness and continuous

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00Pressemelding

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00Pressemelding

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27Pressemelding

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00Pressemelding

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba